Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5764204 | 1.00 | HCAR2 (0.47) | HCAR2MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4256663 | 0.98 | HCAR2 (0.48) | HCAR2MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4256659 | 0.98 | HCAR2 (0.48) | HCAR2MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16414156 | 0.82 | HCAR2 (0.52) | HCAR2MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4256686 | 0.78 | HCAR2 (0.53) | HCAR2MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28157569 | 0.78 | HCAR2 (0.48) | HCAR2MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29022469 | 0.78 | HCAR2 (0.48) | HCAR2MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4256679 | 0.78 | HCAR2 (0.53) | HCAR2MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1801877 | 0.73 | HCAR2 (0.60) | HCAR2MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12018827 | 0.73 | HCAR2 (0.60) | HCAR2MAPTNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309564-B1 | ARYLETHENE-SULFONAMIDES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-06-14 | — | — | EP | disclosed |
| US-6951856-B2 | Arylethene-sulfonamides | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-10-04 | — | — | US | disclosed |
| US-20030220359-A1 | Novel arylethene-sulfonamides | ACTELION PHARMACEUTICALS LTD. (CH) | 2003-11-27 | — | — | US | disclosed |
| EP-1309564-A2 | ARYLETHENE-SULFONAMIDES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002008200-A2 | ARYLETHENE-SULFONAMIDES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220359-A1 | Novel arylethene-sulfonamides | EDNRA, ECE2, ECE1 | HCAR2 192/4885MAPT 4258/4885NPC1 3096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.